Slate Medicines

News

Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.

News

uniQure's latest data drop for its gene therapy for Huntington's disease, under review in the US and UK, has spooked investors.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.